Rubius Therapeutics, Inc. (RUBY)
| Market Cap | 1.21B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -182.07M |
| Shares Out | 89.87M |
| EPS (ttm) | -1.99 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 188,953 |
| Open | 13.21 |
| Previous Close | 13.11 |
| Day's Range | 12.87 - 13.49 |
| 52-Week Range | 6.21 - 38.71 |
| Beta | 2.57 |
| Analysts | Buy |
| Price Target | 30.40 (+126.4%) |
| Earnings Date | Nov 8, 2021 |
About RUBY
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for RUBY stock is "Buy." The 12-month stock price forecast is 30.40, which is an increase of 126.36% from the latest price.
News
Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts by the Boston Globe and Top 3 Best Place...
Company Earns Spot on Both Lists for Second Year in a Row Company Earns Spot on Both Lists for Second Year in a Row
Rubius Therapeutics to Host Virtual Preclinical Pipeline and Platform Technology Day on December 16, 2021
CAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an enti...
Rubius Therapeutics to Participate in Evercore ISI 4th Annual HealthCONx Conference
CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an enti...
Rubius Therapeutics Presents Preclinical Data for RTX-224, a Broad Immune Costimulatory Agonist, at the Society for I...
U.S. FDA Recently Cleared Investigational New Drug Application for RTX-224 U.S. FDA Recently Cleared Investigational New Drug Application for RTX-224
Rubius Therapeutics to Participate in Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an enti...
Rubius Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
U.S. Food and Drug Administration (FDA) Clears Investigational New Drug Application for RTX-224, Rubius' Third Oncology Candidate Clinical Results Expected by Year-End or First Quarter 2022 in Phase 1 T...
Is a Surprise Coming for Rubius Therapeutics (RUBY) This Earnings Season?
Rubius Therapeutics (RUBY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Rubius Therapeutics to Announce Third Quarter 2021 Financial Results
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an enti...
Rubius Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference and H.C. Wainwright...
CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ent...
Rubius Therapeutics Appoints Jim Jogerst as Chief Business Officer
CAMBRIDGE Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entir...
Rubius Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Patients with Advanced Solid Tumors
Should You Buy Rubius Therapeutics (RUBY) Ahead of Earnings?
Rubius Therapeutics (RUBY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates
Let us take a look at some drug/biotech stocks - FSTX, HALO, KNTE, RUBY and SPRB - that are poised to beat on second-quarter earnings.
Rubius Therapeutics to Announce Second Quarter 2021 Financial Results
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an enti...
Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy
Preclinical Data Show RTX-240 Promotes T Cell and NK Cell Activity Demonstrating Efficacy and Improved Safety Compared with a 4-1BB Agonist Antibody Preclinical Data Show RTX-240 Promotes T Cell and NK ...
Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoi...
CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entir...
Rubius Therapeutics to Participate in Jefferies Virtual Healthcare Conference
CAMBRIDGE, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entir...
Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive...
CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entire...
4 Biotech Stocks That Have Already Doubled This Year So Far
Stocks of BioNTech (BNTX), Ocugen (OCGN), Rubius Therapeutics (RUBY) and Entera Bio (ENTX) are up more than 100% this year so far.
Rubius Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
Positive Initial Data from Phase 1/2 Trial of RTX-240 in Advanced Solid Tumors Demonstrated Single-Agent Activity Providing Initial Validation of the RED PLATFORM®;Dose Optimization and Enrollment Conti...
Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Po...
CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an enti...
Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advance...
CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an enti...
FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings
Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY) was among the biggest ...
3 Biotech Stocks to Avoid Right Now
Here's why these attention-grabbing stocks could be toxic to your portfolio.
Implied Volatility Surging for Rubius Therapeutics (RUBY) Stock Options
Investors need to pay close attention to Rubius Therapeutics (RUBY) stock based on the movements in the options market lately.